Posts by Sandra Ansanay-Alex
AMF Medical SA bought for CHF 200 million by Tandem Diabetes Care
Tandem Diabetes Care, a global US-Based insulin delivery and diabetes technology company, announced an agreement to acquire AMF Medical SA, the privately held Swiss developer of the Sigi™ Patch Pump based at EPFL Innovation Park in Lausanne. The full agreement could reach CHF 200 million but is subject to future technical developments and FDA approval…
Read MoreSwiss research: the pharmaceutical industry is the leading investor in 2021
In 2021, private companies spent CHF 16.8 billion in Switzerland on in-house research and development (R&D) activities. This represents an increase of +4% per year since 2019, the year of the last survey, according to a survey carried out by the Federal Statistical Office (FSO) in partnership with economiesuisse. With an amount of CHF 6.2…
Read MoreFuture of Health Grant
The Future of Health Grant programme aims to accelerate start-ups with a digital health solution. Apply before 31 July 2025. Founded in 2022 by EPFL Innovation Park and CSS, the Future of Health Grant offers startups the financial and operational support they need at every stage—from concept inception to market validation. Beyond financial backing, the…
Read MoreNanolive selected in the top 10 Innovations by The Scientist
The Scientist magazine announced its top 10 new products selected by a panel of independent judges. The Lausanne-based start-up Nanolive is Number 5. Over the past decade, Nanolive has developed imaging platforms based on technologies that reconstruct three-dimensional holo-grams of label-free samples. In September 2021, they launched their first application-specific digital assay, LIVE T Cell…
Read MoreMRM wins the Debiopharm – La Solution – Inartis Challenge
The 7th Debiopharm-La-Solution.ch-Inartis Challenge for the Quality of Life of Patient has rewarded with a prize of CHF 25’000 the MRM project. It was selected among 5 finalists who, last July, received 5000 Swiss francs each to develop a prototype. The winner was selected by a jury of healthcare and media professionals from among…
Read MoreVR training for new Lonza employees
How to attract and retain talented workers in the Biotech Industry? And how to train the new recruits efficiently? Lonza in Visp in Switzerland created a Virtual Reality training tool. So far, 250 people were able to train with this new technology. Michael Moedler, Head of Training at Lonza. How did the project started? We were…
Read MoreInnosuisse, what changes in 2023?
As of January 2023, Innosuisse is evolving. Grants will be distributed for international projects, and the financing of start-ups will be strengthened. The revised federal law on the promotion of research and innovation (LERI) will come into effect in January 2023. Here are the main evolutions. Innovation projects Innovation projects are today financed…
Read MoreAlliance, your partner for your Innosuisse application
You have an innovative project and are thinking of submitting an Innosuisse application? With its team of specialized advisors, Alliance is your ally! Between 2020 and 2021, the EPFL based association has raised over CHF 57 million for Swiss SMEs. What is Alliance and how was the structure created? Alliance is the technological innovation…
Read MoreDomo Health: a digital platform for home health
Lack of resources and staff, aging population, an increase in chronic diseases: the challenges of the medical world are numerous and the situations to be managed are increasingly complex. Domo Health develops a digital health platform powered by artificial intelligence. It collects, processes and analyses data from patients and healthcare professionals to optimise prevention, diagnosis,…
Read MoreGeNeuro starts a clinical trials for its long COVID treatment
200 patients are recruited and will be followed in 5 Swiss hospitals participating in the study. The first results are expected during the second semester 2023. GeNeuro is a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of…
Read More